 Englewood Cliffs, NJ, Jan. 06, 2021 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTCQB: SILO a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharmas patent applications relates to using a novel peptide with Psilocybin as a therapeutic. 